HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS CONFERENCE CALENDAR
LATEST UPDATES » Vol 21, No 04, April 2017 – Diabetes: The Big Picture       » ASEAN+ Rare Disease Network Established       » New Superbug Could Be Epidemic       » China Building World's Largest Multifunctional Nano Research Facility       » NUS Study: Daily Consumption of Tea Protects the Elderly from Cognitive Decline       » Diabetes in Your DNA?       » Wearable Biosensors Can Tell You When to See the Doctor      
INSIDE INDUSTRY
VABIOTECH licenses cell-based Japanese encephalitis technology from Inviragen
The Company for Vaccine and Biological Production No.1 (VABIOTECH) will acquire rights to Inviragen's proprietary Japanese encephalitis (JE) technology to produce a cell-derived vaccine from a licensing agreement signed between the two companies. A cell-based JE vaccine has the potential to offer improved manufacturing consistency and safety due to the reduced contaminant, preservatives and unnecessary excipients present compared to the previous generation of animal-derived JE vaccines. Under the terms of the agreement, VABIOTECH may exclusively develop and commercialize JE vaccine based on this technology in Vietnam, Cambodia and Myanmar. In exchange, Inviragen will receive certain development-based milestone payments from VABIOTECH.

“The technology licensed from Inviragen will help advance our JE vaccine production technology,” commented Professor Dr. Nguyen Thu Van, director general of the Company. “In partnership with the Ministry of Health, we have made great strides to control the spread of JE infection in Vietnam. We look forward to incorporating this vaccine technology from Inviragen into our JE program.”

Dr. Dan Stinchcomb, CEO at Inviragen added, “Inviragen is committed to developing vaccines for viral diseases, such as JE, that pose significant health risks worldwide. By partnering with companies such as VABIOTECH that have expertise in vaccine production and a local presence in areas where JE is endemic, our vaccine technology can be put to use where it is most needed.”

“The WHO estimates that there are 68,000 severe clinical cases of JE annually in Asia, causing 10,000 – 15,000 deaths per year. In addition, 30% of the severe infections cause long-lasting neurological damage,” noted Dr. Joseph Santangelo, COO at Inviragen. “VABIOTECH's experience in vaccine manufacturing and commitment to technological advancement makes them an ideal partner for our JE vaccine technology.”

Click here for the complete issue.

NEWS CRUNCH  
news Healthcare Sustainability in Asia: Now is the Time to Act — FT Asia Healthcare & Life Sciences Summit 2017
news Philip Morris International and British American Tobacco receive award from PETA science group for AOP developments
news 6th Asia-Pacific Breast Cancer Summit to take place in Hong Kong
PR NEWSWIRE  
Asia Pacific Biotech News
EDITORS' CHOICE  

Lady Ganga: Nilza'S Story
COLUMNS  
Subscribe to APBN E-Newsletter
Find us under 'Others' option to receive APBN e-newsletters thrice a month!

APBN Editorial Calendar 2017
January:
Healthcare Focus: LUNGS
February:
War on CANCER
March:
Get to Know TCM
April:
Diabetes: The Big Picture
May:
The Piece of Your Mind - Brain Health/Science
June:
Rare Diseases
July:
Food Science & Technology
August:
Eye Care/ Eye Health
September:
No. 1 Killer - Heart Diseases, Diagnosis and Treatment
October:
Skin Diseases/Allergic Reactions
November:
Diseases threatening our Children
December:
Liver Health & Treatment/Technology
Editorial calendar is subjected to changes.
– Editor: Carmen, Jia Wen Loh
MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   biotech_edit@wspc.com or Ms Carmen
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   biotech_ad@wspc.com
Copyright© 2017 World Scientific Publishing Co Pte Ltd  •  Privacy Policy